Brodalumab for immune-related side effects from cancer treatment
Part of Brain & nervous system, Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Mouth & dental, Skin, Women’s health & pregnancy clinical trials.
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of immune-related side effect from cancer immunotherapy that doctors think may be linked to IL-17
- You have a confirmed advanced or metastatic solid organ cancer (cancer that has spread) and have been treated with immunotherapy
- You are not being treated for cancer with intent to cure (treatment aimed at completely removing the cancer)
- You have a negative test for tuberculosis (TB) or are determined to be at low risk for active TB based on specific criteria
- You do not have active suicidal thoughts, severe depression, or a history of attempted suicide
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug that boosts your immune system against cancer (PD-L1 inhibitor) combined with radiation therapy, with or without a bile acid supplement (ursodeoxycholic acid), for patients with advanced HER2-negative breast cancer. The goal is to see if this combination helps control the cancer.
This early-phase study tests a combination of three immune “checkpoint” medicines in people with advanced solid cancers. It aims to see how well they work and what side effects occur, including when given through a specific liver-focused treatment in eligible patients.
This early-phase trial tests a treatment called MORAb-202, an antibody “delivery” drug, to see if it’s safe and can help shrink or control certain advanced cancers. It may help people whose tumors match the study’s specific cancer types and prior treatment history.
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
This trial tests a combination of an immunotherapy drug (camrelizumab), a chemotherapy drug (nab-paclitaxel), and an allergy medicine (levocetirizine) for people with triple negative breast cancer that has spread or come back. The goal is to see if adding the allergy medicine helps the treatment work better.
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.